IP Verse

Sirp-Alpha Immunoglobulin Fusion Proteins - EP3180363

The patent EP3180363 was granted to Merck Patent on Sep 14, 2022. The application was originally filed on Aug 14, 2015 under application number EP15750744A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3180363

MERCK PATENT
Application Number
EP15750744A
Filing Date
Aug 14, 2015
Status
Patent Maintained As Amended
Aug 12, 2022
Grant Date
Sep 14, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SCRIPTJun 24, 2020SCRIPT -

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONUS2015266942
INTERNATIONAL-SEARCH-REPORTUS2014161805
INTERNATIONAL-SEARCH-REPORTWO2010130053
INTERNATIONAL-SEARCH-REPORTWO2014121093
OPPOSITIONUS2003026803
OPPOSITIONWO2009046541
OPPOSITIONWO2009131453
OPPOSITIONWO2010070047
OPPOSITIONWO2010130053
OPPOSITIONWO2013109752
OPPOSITIONWO2014094122
OPPOSITIONWO2014121093
OTHEREP3180363
OTHERWO2014121093
OTHERWO2015148416

Non-Patent Literature (NPL) Citations (6) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Kipp Weiskopf et al, "Engineered SIRP[alpha] variants as immunotherapeutic adjuvants to anticancer antibodies.", Science, American Association for the Advancement of Science, US, US, (20130705), vol. 341, no. 6141, doi:10.1126/science.1238856, ISSN 1095-9203, pages 88 - 91
OPPOSITION- Liu, Y. et al, "Functional Elements on SIRP@a IgV Domain Mediate Cell Surface Binding to CD47", Journal of Molecular Biology, Academic Press, United Kingdom, United Kingdom, (20061223), vol. 365, no. 3, doi:10.1016/j.jmb.2006.09.079, ISSN 0022-2836, pages 680 - 693
OPPOSITION- Mark P Chao, Weissman Irving L, Majeti Ravindra, "The CD47-SIRPĪ± pathway in cancer immune evasion and potential therapeutic implications", Current Opinion in Immunology, Elsevier Current Trends, (20120401), vol. 24, no. 2, doi:10.1016/j.coi.2012.01.010, ISSN 09527915, pages 225 - 232
OPPOSITION- Mark P Chao, Weissman Irving L, Majeti Ravindra, "The CD47-SIRPĪ± pathway in cancer immune evasion and potential therapeutic implications", Current Opinion in Immunology, Elsevier Current Trends, (20120401), vol. 24, no. 2, doi:10.1016/j.coi.2012.01.010, ISSN 09527915, pages 225 - 232, XP055029985
OPPOSITION- Liu, Y. et al, "Functional Elements on SIRP@a IgV Domain Mediate Cell Surface Binding to CD47", Journal of Molecular Biology, Academic Press, United Kingdom, United Kingdom, (20061223), vol. 365, no. 3, doi:10.1016/j.jmb.2006.09.079, ISSN 0022-2836, pages 680 - 693, XP005733360
OPPOSITION- Kipp Weiskopf et al, "Engineered SIRP[alpha] variants as immunotherapeutic adjuvants to anticancer antibodies.", Science, American Association for the Advancement of Science, US, US, (20130705), vol. 341, no. 6141, doi:10.1126/science.1238856, ISSN 1095-9203, pages 88 - 91, XP002745510

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patentā€™s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patentā€™s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents